Venture Life Group PLC

Venture Life Group PLC

VLG · LSE · Consumer Defensive / Household & Personal Products

69.00GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close69.00
Open69.00
Day Range68.25 – 69.28
52-Week Range52.00 – 72.00
Volume60.28K
Market Cap83.03M
P/E (TTM)0.00
Forward P/E9.96
EPS-0.01
Dividend Yield0.00%
Beta0.17
50-Day Avg67.51
200-Day Avg65.89

About

Venture Life Group plc develops and commercializes healthcare products in the United Kingdom. The company offers oral healthcare products, including mouthwash, toothpaste, breath freshening capsules, and dental accessories under UltraDEX and Dentyl Dual Action brands; and proctology products, such as Procto-eze Plus range for treating the discomfort caused by haemorrhoids. It also provides dermatology products comprising Myco Clear, a fungal nail cleanser and solution brand; Rosa calma for normalizing and controlling the signs and symptoms related to rosacea; Bioscalin for the cosmetic treatment and prevention of hair loss, hair thinning, and baldness; and skincare solutions under the brand Lubatti. In addition, the company offers women's healthcare products, including BV treatment gel and pessaries; intimate daily wash and soothing cream; moisture gel and plus pessaries; and thrush cream under Balance Activ name. Further, it provides glucose management products, such as Lift Glucose shots and tablets for the immediate treatment of hypoglycaemia and preventing hypos; Glucogel for the treatment of hypoglycaemia. Additionally, the company offers ENT care products comprising Earol, for the removal of ear wax; EarolSwim, an invisible ear plugs for protecting the ears from water ingress; and Baby Earol, an ear spray for babies under the Earol and EarolSwim brands. It also provides oncology support products, such as Pomi-T for the management of prostate-specific antigen levels in prostate cancer; Gelclair, a muco-adhesive oral rinse for the treatment of Oral Mucositis; and Xonrid, a hyaluronic acid-based topical gel, for the prevention and treatment of radiation-induced dermatitis. The company operates in Germany, the Netherlands, France, Sweden, Denmark, Lithuania, rest of Europe, the United States, Canada, Brazil, Ireland, and internationally. Venture Life Group plc was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.

Company Details

  • SectorConsumer Defensive
  • IndustryHousehold & Personal Products
  • CEOMr. Jeremy Anthony Philip Randall ACA
  • Employees43
  • Headquarters12 The Courtyard, Bracknell, United Kingdom, RG12 2XB, UK
  • Websitehttps://www.venture-life.com

Leadership

  • Mr. Jeremy Anthony Philip Randall ACACo-Founder, CEO & Executive Director · b. 1964
  • Mr. Daniel James WellsCFO & Director · b. 1987
  • Mr. Peter JacksonChief Digital & Technology Officer
  • Ben ColmanDirector of Corporate Development
  • Ms. Katherine Louise BacheChief Marketing & Innovation Officer and Director · b. 1981
  • Mr. Domenico BarbaroHead of Procurement
  • Mr. Ennio SchiroHead of ESG Strategy
  • Mr. Matt JeffsHead of M&A
  • Louise McCarthyCompany Secretary

Financials

Income Statement

Currency: GBP2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue101.00K395.00K292.00K486.00K7.19M9.08M14.28M16.05M18.77M20.21M30.08M32.76M43.98M51.41M26.59M35.17M
Growth (%)-+291.09%-26.08%+66.44%+1379.22%+26.26%+57.32%+12.41%+16.93%+7.65%+48.85%+8.93%+34.24%+16.89%-48.27%+32.24%
Cost of Revenue85.00K240.00K173.00K301.00K4.54M6.07M8.79M9.58M11.48M12.20M17.23M19.80M26.32M31.26M14.41M23.37M
Gross Profit16.00K155.00K119.00K185.00K2.65M3.00M5.49M6.47M7.29M8.00M12.85M12.96M17.66M20.15M12.19M11.79M
Gross Margin15.84%39.24%40.75%38.07%36.92%33.09%38.45%40.31%38.83%39.61%42.72%39.55%40.17%39.19%45.82%33.54%
Operating Expense224.00K572.00K906.00K1.28M4.27M4.70M5.96M5.89M6.24M6.72M9.29M11.59M15.44M16.86M10.67M10.75M
Operating Income-208.00K-417.00K-787.00K-1.10M-1.62M-1.69M-465.00K581.00K1.05M1.28M3.56M1.37M2.23M3.29M1.51M1.05M
Operating Margin-205.94%-105.57%-269.52%-225.93%-22.51%-18.66%-3.26%3.62%5.60%6.32%11.82%4.18%5.06%6.40%5.70%2.97%
EBITDA-193.00K-371.00K-731.00K-1.04M-815.00K-713.00K573.00K1.77M2.60M2.79M5.60M5.16M7.61M9.95M4.32M5.08M
EBITDA Margin-191.09%-93.92%-250.34%-213.37%-11.34%-7.86%4.01%11.03%13.87%13.83%18.62%15.76%17.31%19.35%16.25%14.46%
Net Income-209.00K-417.00K-788.00K-1.08M-1.57M-1.76M-1.37M-367.00K236.00K904.00K2.37M2.40M520.00K921.00K-314.00K6.13M
Net Income Margin-206.93%-105.57%-269.86%-222.43%-21.84%-19.40%-9.59%-2.29%1.26%4.47%7.87%7.33%1.18%1.79%-1.18%17.42%
R&D-47.00K272.00K48.00K493.00K326.00K426.00K387.00K237.00K194.00K871.00K724.00K791.00K303.00K176.00K-
R&D as % of Total Revenue-11.90%93.15%9.88%6.86%3.59%2.98%2.41%1.26%0.96%2.90%2.21%1.80%0.59%0.66%-
Interest Expense--1.00K25.00K81.00K95.00K644.00K518.00K341.00K68.00K333.00K514.00K1.52M2.18M1.50M1.49M
Interest Expense % of Total Revenue--0.34%5.14%1.13%1.05%4.51%3.23%1.82%0.34%1.11%1.57%3.46%4.24%5.63%4.22%

Balance Sheet

Currency: GBP2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets684.00K752.00K692.00K2.00M24.05M21.92M27.35M31.31M45.65M47.03M92.68M103.63M125.29M119.50M124.49M99.18M
Total Liabilities472.00K440.00K565.00K1.44M8.41M8.12M12.99M17.12M13.56M14.21M20.57M30.47M49.63M43.24M49.08M17.76M
Total Equity212.00K312.00K127.00K557.00K15.65M13.80M14.36M14.19M32.08M32.82M72.11M73.16M75.66M76.25M75.41M81.42M
Cash151.00K97.00K84.00K453.00K4.93M2.86M2.00M1.36M9.62M5.16M42.09M5.24M5.63M5.62M3.05M34.17M
Total Debt57.00K4.00K4.00K352.00K3.86M3.26M7.14M11.38M7.07M7.03M11.18M12.73M26.85M24.39M23.86M667.00K
Net Debt-94.00K-93.00K-80.00K-101.00K-1.08M403.00K5.15M10.02M-2.56M1.87M-30.92M7.49M21.21M18.77M20.81M-33.50M

Cash Flow

Currency: GBP2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-250.00K-479.00K-516.00K-1.03M-2.22M-1.11M-457.00K-84.00K238.00K2.44M2.71M601.00K5.57M8.22M8.35M-264.00K
Investing Cash Flow1.00K-51.00K-23.00K-177.00K-2.98M-571.00K-4.79M-853.00K-5.21M-1.15M-7.53M-39.18M-11.69M-5.34M-11.29M53.98M
Financing Cash Flow386.00K476.00K526.00K1.58M9.73M-327.00K4.31M252.00K13.23M111.00K36.27M1.50M6.92M-2.81M1.78M-23.77M
Capital Expenditure3.00K6.00K24.00K147.00K609.00K592.00K540.00K853.00K1.01M1.15M2.07M3.26M4.21M2.41M10.00K45.00K
Free Cash Flow-253.00K-485.00K-540.00K-1.18M-2.83M-1.70M-997.00K-937.00K-777.00K1.30M637.00K-2.66M1.36M5.81M8.34M-309.00K
Dividends Paid--5.00K5.00K12.00K14.00K14.00K15.00K14.00K-------
FCF to OCF101.20%101.25%104.65%114.20%127.38%153.38%218.16%1115.48%-326.47%53.09%23.54%-442.76%24.43%70.72%99.88%117.05%
Dividend Paid to FCF---0.93%-0.42%-0.42%-0.82%-1.40%-1.60%-1.80%-------

Earnings

Report DateMay 9, 2016Sep 21, 2016May 2, 2017Sep 19, 2017Mar 21, 2018Sep 19, 2018Mar 21, 2019Sep 19, 2019Apr 9, 2020Sep 24, 2020Apr 5, 2021Sep 22, 2021Mar 24, 2022Sep 29, 2022Mar 28, 2023Sep 30, 2024Jun 19, 2025Sep 30, 2025Nov 13, 2025Mar 31, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.000.00-0.000.000.00-0.00-0.000.000.00
EPS Actual-0.02-0.03-0.01-0.020.01-0.010.010.000.010.020.010.000.020.000.01-0.01-0.010.020.050.00
Surprise--------------------
Timing------------Pre-marketAfter-hoursAfter-hours-Pre-market---

Key Statistics & Ratios

Market Cap83.03M
Enterprise Value47.88M
Trailing P/E0.00
Forward P/E9.96
Price / Sales2.35
Price / Book1.00
EPS-0.01
Book Value0.617
Revenue (TTM)35.27M
Gross Profit (TTM)15.75M
EBITDA4.78M
Profit Margin6.83%
Operating Margin-16.02%
Return on Equity-2.44%
Return on Assets0.86%
Shares Outstanding118.62M
Shares Float104.97M
Beta0.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20181×
0.00May 24, 2018
20171×
0.00May 25, 2017
20161×
0.00May 26, 2016
20151×
0.00May 21, 2015
20141×
0.00Jun 11, 2014

Stock Splits

  • Nov 23, 2020722:721